期刊
JACC: CARDIOONCOLOGY
卷 3, 期 4, 页码 522-533出版社
ELSEVIER
DOI: 10.1016/j.jaccao.2021.05.004
关键词
cardiac amyloidosis; epidemiology; heart failure; outcomes; temporal changes
资金
- Erik og Susanna Olesens AlmenvelgOrende Fond
- National Institutes of Health [R01HL139671, R21AG058348, K24AG036778]
This study in Denmark showed an increasing diagnosis of cardiac amyloidosis, with a higher proportion of male patients and older age at diagnosis over the period of 1998 to 2017. There was also a decrease in 2-year mortality rates among the patients with cardiac amyloidosis.
BACKGROUND Cardiac amyloidosis (CA) has been associated with poor outcomes. Screening studies suggest that CA is overlooked-especially in the elderly. Recent advances in treatment have brought attention to the disease, but data on temporal changes in CA epidemiology are sparse. OBJECTIVES The aim of this work was to describe all patients with CA in Denmark, examining changes in patient characteristics from 1998 to 2017. METHODS All patients with any form of amyloidosis diagnosed from 1998 to 2017, as well as their comorbidities and pharmacotherapy, were identified in Danish nationwide registries. CA was defined as any diagnosis code for amyloidosis combined with a diagnosis code for heart failure, cardiomyopathy, or atrial fibrillation or a procedural code for pacemaker implantation, regardless of the order. The index date was defined as the date of meeting those criteria. Patients were divided into 5-year periods by index date. For comparison, we also included control subjects (1:4 ratio) from the general population. RESULTS CA criteria were met by 619 patients. Comparing 1998-2002 vs 2013-2017, the median age at baseline increased from 67.4 years (interquartile range [IQR]: 53.9-75.2 years) to 72.3 years (IQR: 66.0-79.3 years). The frequency of male patients increased from 62.1% to 66.2%. The incidence of CA rose from 0.88 to 3.56 per 100,000 person-years in the Danish population aged $65 years, and the 2-year mortality decreased from 82.6% (IQR: 69.9%-90.5%) to 50.2% (IQR: 43.1%-56.9%). Compared with control subjects, the mortality among CA patients was significantly higher (log-rank test: P < 0.0001). CONCLUSIONS CA, as defined in this study, was increasingly diagnosed on a national scale. The increasing frequency of male patients and median age suggest that wild-type transthyretin amyloidosis is driving this increase. Greater recognition of earlier, less advanced cases might explain decreasing mortality. (J Am Coll Cardiol CardioOnc 2021;3:522-533) (c) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据